Corey McCann hasn’t just raised a quarter of a billion dollars for just another startup. He has been pioneering a whole new space, Software As A Drug (SaaD). The timing couldn’t be better either.
During our interview on the Dealmakers Show McCann shared his journey into this apex of science, medicine, technology and startups. Including this new software concept, the future of digital therapeutics, what it takes to be successful in startups, strategizing fundraising rounds, and his top tips for other entrepreneurs.
The Swiss Army Knife Of Entrepreneurs
Corey McCann was born and raised in a small town in Pennsylvania. His mother was a biology professor at a local college. While other kids were out doing sports, he was being funneled into science, with plenty of pressure mounting for those annual science projects.
He says he has “always been really interested in the brain, interested in why the brain thinks about what it thinks about.” That took him to study at Penn State. An MD by training, he spent plenty of time in research, and specifically studying molecular and cellular neuroscience. So, he is more of a physician-scientist.
Corey began to see how different technologies could go from cool science projects and become self-sustaining companies with the ability to deliver real impact for people. He also witnessed how venture capital was a discipline and deciding factor in which of these technologies and solutions were able to move forward, or not.
He also noticed that those who were really able to have a deep impact on society were able to handle multiple disciplines. They were able to bring together multiple skills to make things happen.
He began building this other part of his skill set working with RiverVest Venture Partners. He was on the front line, turning piles and piles of pitch decks into smaller piles of pitch decks to be explored more deeply. In the process he became passionate about starting companies and allocating resources to them. He continued pursuing this through working with McKinsey and MPM Capital.
Through the consulting work he learned how to break down big problems and ask the right questions for building a company. His medical training allowed him to see the impact things had directly on patients. The science gave him the power of exploration and answering the questions. The investing work enabled him to put himself in the mind of investors for fundraising and creating value. He effectively forged himself as a Swiss army knife for entrepreneurship in this space.
Digital Therapeutics: Software As A Drug
For brain conditions and diseases treatment has commonly been the combination of experiences and drugs. Or drugs and conversational therapy. These patterns working together create an impact.
What struck this entrepreneur was that people hadn’t really been trying to convert this cognitive experience into the equivalent of a drug.
This concept of Software as a Drug has now become known as Digital Therapeutics.
This was the birth of his company PEAR Therapeutics. A venture dedicated to bringing digital therapeutics to patients.
The initial idea was to begin a fund that would invest in startups in this space. They looked at hundreds of new technologies in this space. They just couldn’t find them with management teams capable of bringing the tech and science to becoming mainstream.
This identified a great gap. So, they began acquiring and licencing these assets and combined them into a shared platform. They began assembling an expert team that brought together all of these disciplines in pharma, tech and healthcare.
So far PEAR has already raised $250M. That includes a recent $80M Series D funding round which was led by Softbank.
See How I Can Help You With Your Fundraising Efforts
- Fundraising Process : get guidance from A to Z.
- Materials : our team creates epic pitch decks and financial models
- Investor Access : connect with the right investors for your business and close them